Safe Harbor Statement

This presentation contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "intend," "target," "will," "is likely," "would," "may," or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements are found at various places throughout this presentation and include information concerning possible or assumed future results of our operations; business strategies; future cash flows; financing plans; plans and objectives of management; any other statements regarding future operations, future cash needs, business plans and future financial results, and any other statements that are not historical facts. Unless otherwise indicated, the terms "CytoSorbents," "Company," "we," "us" and "our" refer to CytoSorbents Corporation. Any or all of the forward-looking statements included in this presentation are not guarantees of future performance and may turn out to be inaccurate. These forward-looking statements represent our intentions, plans, expectations, assumptions and beliefs about future events and are subject to risks, uncertainties and other factors. Many of those factors are outside of our control and could cause actual results to differ materially from the results expressed or implied by those forward-looking statements. Although these expectations may change, we are under no obligation to inform you if they do. Actual events or results may differ materially from those contained in the forward-looking statements. The following factors, among others, could cause our actual results to differ materially from those described in a forward-looking statement: our history of losses; potential fluctuations in our quarterly and annual results; competition, inability to achieve regulatory approval for our device, technology systems beyond our control and technology-related defects that could affect the companies’ products or reputation; risks related to adverse business conditions; our dependence on key employees; competition for qualified personnel; the possible unavailability of financing as and if needed; and risks related to protecting our intellectual property rights or potential infringement of the intellectual property rights of third parties. This list is intended to identify only certain of the principal factors that could cause actual results to differ from those discussed in the forward-looking statements. In light of these risks, uncertainties and assumptions, the events described in the forward-looking statements might not occur or might occur to a different extent or at a different time than we have described. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of the applicable presentation. You are referred to a discussion of important risk factors detailed in the Company's Form 10-K filed with the Securities and Exchange Commission on March 9, 2021 and other reports and documents filed from time to time by us, which are available online at www.sec.gov.
Opening Remarks
Al Kraus
Chairman of the Board
Board of Directors

**Al Kraus – Chairman** (Audit, Governance, Compensation Committees)*

25+ years leadership experience in the dialysis and medical device industries. Former CEO and Board director of CytoSorbents, NOvoVascular, Althin Medical, and former COO and U.S. Subsidiary Manager of Gambro, Inc., one of the leading dialysis companies in the world, taking them public through an IPO in the U.S. in the 1980's and growing sales 4x.

**Michael Bator, MBA** (Compensation Committee)*

Founder and Partner of Quartz Advisory Group, LLC and Certus Advisory. 15 year Wall Street veteran, most recently as Managing Director - Healthcare Research at Jennison Associates, a US mutual and pension fund management company, with $109 billion in equities and $66 billion in fixed income assets. Formerly a management consultant at several agencies, including the Boston Consulting Group.

**Phillip Chan, MD, PhD** – Chief Executive Officer

Former Partner at the $80M NJTC Venture Fund, leading life science investments for 5 years. Co-founder and Vice Chairman of Medality Medical, evaluating its FDA 510(k) cleared HydraSolve™ lipoplasty device in the U.S. for the treatment of Type 2 Diabetes. Internal medicine physician with MD/PhD from Yale School of Medicine, internal medical residency at the Beth Israel Deaconess Medical Center at Harvard.

**Edward Jones, MD, MBA** (Audit, Governance Committees)*

Clinical Professor of Medicine at Temple University Hospital and attending nephrologist at the Albert Einstein Medical Center and Chestnut Hill Hospital. Past President and Managing director of Delaware Valley Nephrology and Hypertension Associations. Past Board member of the National Kidney Foundation of the Delaware Valley, Past President of the Renal Physicians Association, and Chairman of Kidney Care Partners

**Alan Sobel, MS, CPA** (Audit Committee Chair, Governance Committee)*

Audit Committee Chair. Managing Member of Sobel & Co., LLC, a full-service accounting, audit, tax, and business consulting firm serving individuals, small and mid-sized businesses, and SEC-registered companies. Former Chairman of the Audit Committee of the New Jersey Society of Certified Public Accountants

* Independent directors per SEC definition
Leadership Background

Phillip Chan, MD, PhD – Chief Executive Officer
13 year tenure at CytoSorbents. Former Partner of the $80M NJTC Venture Fund. Co-founder and Vice Chairman of Medality Medical, evaluating its US FDA 510(k) cleared HydraSolve™ device to treat Type 2 diabetes. MD/PhD - Yale School of Medicine, internal medical residency - Beth Israel Deaconess Medical Center at Harvard.

Vincent Capponi, MS - Chief Operating Officer and President
25+ years experience in the medical device, pharmaceutical and imaging fields. Led the first regulatory approval for the heparin flush syringe, used worldwide in hospitals, and managed manufacturing of > 1 million units/week

Kathleen Bloch, MBA, CPA – Chief Financial Officer
25+ years as CFO of private and public companies. Former Laureate Biopharma CFO, a contract biopharmaceutical manufacturer, and CFO of Silverline Windows, a $750M revenue window manufacturing company with 9 manufacturing plants nationally

Efthymios “Makis” Deliargyris, MD, FACC, FESC, FSCAI – Chief Medical Officer
20+ years in academia and industry in clinical development of anti-thrombotics and anti-coagulants, and as a cardiologist and interventional cardiologist. Former CMO of PLx Pharma (NASDAQ: PLXP) and Vice President, European Medical Director, and Global Medical Lead - Acute Cardiovascular Care at The Medicines Company

Christian Steiner, MD – Vice President of Sales and Marketing
20+ years experience in sales and marketing of extracorporeal therapy and critical care sales at Teraklin for MARS, the first liver failure dialysis technology, and at Pulsion Medical (hemodynamic monitoring)

Christopher Cramer, MS, MBA – Vice President of Business Development
20+ years experience in business development and commercial experience. Former Senior Director of New Venture Development at Johnson & Johnson, and previously at PwC Consulting, leading life science investments
The Future of CytoSorbents: Opportunities Abound

Phillip Chan, MD, PhD
Chief Executive Officer
CytoSorb is in 68 countries around the world.
Targeting Deadly Conditions Afflicting Millions of People

### Critical Care

Uncontrolled inflammation can spiral out of control, leading to failure of vital organs and death

<table>
<thead>
<tr>
<th>Condition</th>
<th>Image</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sepsis</td>
<td><img src="image" alt="Sepsis" /></td>
</tr>
<tr>
<td>Influenza</td>
<td><img src="image" alt="Influenza" /></td>
</tr>
<tr>
<td>COVID-19</td>
<td><img src="image" alt="COVID-19" /></td>
</tr>
<tr>
<td>Lung Injury</td>
<td><img src="image" alt="Lung Injury" /></td>
</tr>
<tr>
<td>Trauma</td>
<td><img src="image" alt="Trauma" /></td>
</tr>
<tr>
<td>Surgical Complications</td>
<td><img src="image" alt="Surgical Complications" /></td>
</tr>
<tr>
<td>Burn Injury</td>
<td><img src="image" alt="Burn Injury" /></td>
</tr>
<tr>
<td>Cytokine Release Syndrome</td>
<td><img src="image" alt="Cytokine Release Syndrome" /></td>
</tr>
<tr>
<td>Liver Failure</td>
<td><img src="image" alt="Liver Failure" /></td>
</tr>
<tr>
<td>Pancreatitis</td>
<td><img src="image" alt="Pancreatitis" /></td>
</tr>
</tbody>
</table>

### Cardiothoracic Surgery

Highly invasive, with major risk of bleeding, shock, severe inflammation, infection, sepsis, and others

- Life-threatening bleeding due to anti-thrombotic “blood thinners”
- High Risk Procedures
- Post-op infection & shock
- Infective Endocarditis

---

[Image of cytosorbents logo]
Riding Many Macro Trends in Healthcare

**Sepsis by the Numbers 2017**

- **48.9 Million Cases**
- **11 Million Deaths**

1 in every 5 deaths worldwide are associated with sepsis. 85% occur in low- or middle-income countries. 2 out of every 5 cases are in children under 5.

**Blood Thinners**
- coumadin
- heparin
- lovenox
- xarelto
- eliquis
- pradaxa
- plavix
- brilinta
- aggrenox
- aspirin
- TPA

straightnursingstudent.com

**Influenza**

**Bacterial Endocarditis**
- Mitral valve
- Aortic valve

**CytoSorbents**
Our Results Reflect our Potential and Hard Work

We believe there is much more we can accomplish

131,000+ Cumulative Treatments
81% Blended Product Gross Margins
200+ Employees
$68.5M in cash
Product Revenue (TTM)
Our Expansion Reflects our Confidence

CytoSorbents
New Headquarters and Manufacturing Facility
Princeton, NJ

CytoSorbents
New European Logistics Hub
Berlin, Germany
And It Is Our Amazing People
Who Will Get Us There
Well-Positioned for Growth

Kathy Bloch, MBA, CPA
Chief Financial Officer
The annual product sales growth trajectory remains strong.

Q1 2021 gross margin of 81% excludes tariff costs related to prior periods (2020, 2019, and 2018) and non-recurrent employee retention tax credits.
# Year Over Year Financial Progress

<table>
<thead>
<tr>
<th></th>
<th>2021</th>
<th>2020</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Growth Indicators:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TTM Product Sales, March 31</td>
<td>$41,439,889</td>
<td>$26,345,244</td>
<td>$20,395,666</td>
</tr>
<tr>
<td>TTM Product Gross Margin $, March 31</td>
<td>$31,470,137</td>
<td>$20,310,029</td>
<td>$15,028,169</td>
</tr>
<tr>
<td>Product Gross Margin %, Q1*</td>
<td>81%</td>
<td>76%</td>
<td>74%</td>
</tr>
<tr>
<td><strong>Liquidity Indicators:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and Cash Equivalents, March 31</td>
<td>$68,468,285</td>
<td>$26,389,021</td>
<td>$19,647,374</td>
</tr>
<tr>
<td>Net Working Capital, March 31</td>
<td>$69,875,527</td>
<td>$26,064,951</td>
<td>$18,116,861</td>
</tr>
<tr>
<td>Debt Outstanding, March 31</td>
<td>$0</td>
<td>$15M</td>
<td>$15M</td>
</tr>
<tr>
<td><strong>Value Indicator:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Market Capitalization, May 31</td>
<td>$350M</td>
<td>$375M</td>
<td>$203M</td>
</tr>
</tbody>
</table>

*Q1 2021 gross margin of 81% excludes tariff costs related to prior periods (2020, 2019, and 2018) and non-recurrent employee retention tax credits*
Strong Foundation to Execute on Growth Plan

• The Company is well-capitalized, with $68.5M in cash at March 31, 2021

• Our cash-on-hand provides adequate funding to execute our robust clinical and commercialization plans over the coming years

• We believe our existing cash balance is adequate to fund our activities through to the achievement of GAAP breakeven which we expect to reach within two years

• Given our 80%+ gross margins, we expect to generate strong cash flow from operations that is expected to continue increasing as sales grow
The CytoSorbents Growth Story

Christian Steiner, MD
Executive Vice President – Sales and Marketing
> 131,000
CytoSorb treatments since 2011

+ 49%
since April 1st 2020
Trailing 12-month total:
CytoSorb Treatments

Q1 2012: $M
Q1 2013: $M
Q1 2014: $M
Q1 2015: $M
Q1 2016: $M
Q1 2017: $M
Q1 2018: $M
Q1 2019: $M
Q1 2020: $M
Q1 2021: $M

+58%
+31%
+33%
+46%
CytoSorb growth rates exceed industry averages

- **Accelerated revenue growth** both in TOTAL and CORE business while medical device industry declines by more than 3%* in 2020

- CTSO revenue **CAGR >35%** (>45% incl. COVID) is outpacing the medical device industry CAGR of 4-6%*

- **Stable pricing** and continued improvement of cost structure enables high gross margins

- Core business growth is based on **increased market penetration** in traditional indications supported by geographical expansion

---

* FORTUNE Business Insights: Market Research Report Medical Devices 2020, May 2021
CytoSorbents growth could benefit from COVID

**Short term impact**

- Additional revenues due to the treatment of more than 6,000 patients worldwide up to date
- CytoSorb Therapy endorsed and included in COVID therapy guidelines in several countries
- Additional registrations for therapy of COVID-19 patients such as in the United States, Canada, Israel and India
CytoSorbents growth could benefit from COVID

**Mid term scenarios**

- **Increase of patient numbers** for core indications due to:
  - Ramp up of elective surgery programs (were down 30-40%)
  - Usual incidences of pneumogenic sepsis, influenza and others
  - Full ICU capacity available again

- Re-established **access to** actual and potential **customers**

- **Re-start of commercial campaigns** and initiatives (ATR, Liver) as well as **clinical programs** which were on hold
CytoSorbents growth could benefit from COVID

**Long term effects**

- **Significant awareness increase** for CytoSorb Therapy
- **Cytokine Storm** became an acknowledged **therapy target**
- Additional **registrations** in certain markets are expected to stay effective
- **Organizational and process** adaptations and changes during the pandemic can make the ‘New Normal’ commercialization more effective
Ready for further growth

- **CTSO team** with exceptional expertise across all fields

- **New Production** in Princeton, NJ, United States

- **New CytoSorbents Logistic Hub** in Berlin, Germany

- **Additional sales and marketing channels** established

- **Start of new high potential markets:**
  - Singapore, Brazil, South Korea, Others

- **Campaigns** are expected to generate additional business
  - Anti-thrombotic Removal
  - Liver Support

- New application fields are currently being prepared
Fueling Growth with FDA Approval(s) and Data

Efthymios “Makis” Deliargyris, MD
Chief Medical Officer
# Dual Path to U.S. FDA Approval

<table>
<thead>
<tr>
<th>Indication STUDY</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Post-operative AKI REFRESH-2</td>
<td>• Actively enrolling - 154 patients enrolled to date</td>
</tr>
<tr>
<td></td>
<td>• 50% of study sites already actively screening and enrolling</td>
</tr>
<tr>
<td></td>
<td>• Remaining sites to be activated by end of Q2</td>
</tr>
<tr>
<td></td>
<td>• Next milestone: Interim Analysis</td>
</tr>
<tr>
<td>Ticagrelor Removal STAR-T</td>
<td>• Investigational plan in the spirit of the Breakthrough Designation (Clinical data to address unmet medical need)</td>
</tr>
<tr>
<td></td>
<td>• IDE Conditional approval Apr ’21 (green light to start)</td>
</tr>
<tr>
<td></td>
<td>• Sites identified and initiation activities (IRB submission and site contracting) in progress</td>
</tr>
<tr>
<td></td>
<td>• Operations: Study vendors selected</td>
</tr>
<tr>
<td></td>
<td>• Study committees established (DSMB &amp; CEC)</td>
</tr>
<tr>
<td></td>
<td>• Full IDE approval expected imminently - FPI Q3 ’21</td>
</tr>
</tbody>
</table>

We believe **STAR-T represents the lowest risk and fastest path to FDA approval and will set precedent for upcoming trials to unlock the full Antithrombotic Removal opportunity**
STAR-T “World-Class” Academic Leadership

C. Michael Gibson, MS, MD
Interventional Cardiologist

Michael Mack, MD
Cardiothoracic Surgeon

Co-Pl’s Heart-Team Approach

- Professor of Medicine, Harvard Medical School
- President & CEO of non-profit Baim Institute (formerly Harvard Clinical Research Institute)
- Founder, Editor-In-Chief www.wikidoc.org

Principal Investigator or Executive Committee member in multiple antithrombotic drug pivotal studies leading to FDA approvals including prasugrel (Effient®, Daiichi Sankyo, Eli Lilly), rivaroxaban (Xarelto®, Bayer, Jannsen), betrixaban (Bevyxxa®, Astra Zeneca), and andexanet alfa (Andexxa®, Astra Zeneca)

- Chair, Cardiovascular Service Line, Baylor Scott & White Health
- President, Baylor Scott & White Research Institute
- Pioneer of the “Heart Team” approach

Principal Investigator or Executive Committee member in multiple transcatheter valve device pivotal studies leading to FDA approvals including the Sapien aortic valve replacement system (Edwards Lifesciences) and the Mitraclip mitral valve repair system (Abbott)
## 2021 – Rich in Clinical Milestones

Complementary approach to data generation: RCT, Registries, Single arm trials

### 2021

<table>
<thead>
<tr>
<th></th>
<th>Q1</th>
<th>Q2</th>
<th>Q3</th>
<th>Q4</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cardiovascular</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STAR-T</td>
<td>Protocol</td>
<td>IDE Submission &amp; Approval</td>
<td>Operational Readiness</td>
<td>FPI</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Enrollment</td>
</tr>
<tr>
<td>REFRESH II</td>
<td>Protocol</td>
<td>Study Resumption Activities</td>
<td>FPI</td>
<td>Enrollment</td>
</tr>
<tr>
<td>CYTATION</td>
<td>Operational Readiness</td>
<td>FPI</td>
<td>Enrollment</td>
<td></td>
</tr>
<tr>
<td>STAR Registry</td>
<td>Protocol</td>
<td>EC Submission Operational Readiness</td>
<td>FPI</td>
<td>Enrollment</td>
</tr>
<tr>
<td><strong>Critical Care</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PROCYSS</td>
<td>Protocol</td>
<td>EC Submission and Operational Readiness</td>
<td>FPI</td>
<td>Enrollment</td>
</tr>
<tr>
<td>Hep-On-Fire</td>
<td>Protocol</td>
<td>EC Submission and Operational Readiness</td>
<td>FPI</td>
<td></td>
</tr>
<tr>
<td>CTC/CTCC Registry</td>
<td>CTC Enrollment</td>
<td>Publication submission</td>
<td>CTC/CTCC Ongoing Enrollment</td>
<td></td>
</tr>
</tbody>
</table>

All clinical programs have either achieved, or on track to hit 2021 milestones
2021 - Key Clinical Team Hires

Victoria Lee, MD – Director, Clinical Affairs
Board certified in vascular surgery. Previously served as Associate Medical Director at Syntactx, a cardiovascular device CRO, and as Medical Consultant, McKinsey and Company. Education: University of Washington, NYU, Harvard.

Ed Tumaian – Executive Director, Global Clinical Operations
25+ years experience in clinical development and operations. Previously held leadership roles in clinical operations at both CRO (Quintiles, Parexel) and pharma sponsors (Novartis, AstraZeneca, Sanofi). Lifecycle management of multiple blockbuster products including Prilosec, Nexium, Plavix, and Gleevec. Education: Villanova

Hans Kroger, MSc, MPH – Senior Director, Biostatistics & Data Management
19+ years experience in biostatistics and data management. Previously held leadership roles at Sun Pharma, PTC Therapeutics, Sunovion and PRA health sciences. Education: Penn State, Emory, Columbia
Robust Clinical Plan to Drive Growth

• Unlocking the U.S. market with FDA approval for ticagrelor removal in cardiac surgery (STAR-T)
  • World class team to ensure rigorous and fast trial execution
  • U.S. DOAC removal study follows leveraging STAR-T framework
  • HECON modelling initiated to validate large value proposition of antithrombotic removal in U.S. cardiac surgery practice

• Data generation in Critical care & CV to drive business growth
  • U.S. multicenter data on CytoSorb + ECMO in COVID-19 (CTC)
  • RCT data from Germany on CytoSorb in septic shock (PROCYSS)
  • Clinical data to unlock the large opportunity in liver (HepOnFire)
  • Real world evidence generation with dedicated Registries in Critical Care (CTCC) and Antithrombotic Removal (STAR)

• Expanded global Clinical/Medical capabilities and footprint
  • Global team has doubled in size in 2021 and will continue to grow with the intent of driving timely and superior execution of clinical goals
  • Growing KOL advocacy in Critical Care and Cardiovascular Medicine
Driving Growth Through U.S. Commercialization and Operational Excellence

Vincent Capponi, MS
President and Chief Operating Officer
Key Hires

James Komsa, MBA – VP Marketing and Sales
• 25+ years of Executive Sales and Marketing Leadership at Small and Large Cap (Medtronic) Medical Device Companies
• Early Career Venture Cap backed high growth medical device successes sold to Philips and Medtronic
• 10 years as VP Cardiac and Vascular Group-Medtronic, responsible for Pacemakers, Defibrillators, Stents, Valves, Cardiac Surgery, Perfusion, >$300+M/Yr
• 5+ years as Americas VP Interventional Spine, Spine, Biologics, Oncology product lines, signed agreement with AmGen, >$350M/Yr
• 5+ years as VP Restorative Therapies Group, Spine, Biologics, ENT, Pain, Neuromodulation, Navigation, Imaging, Robotics, >$450M/Yr

David Cox, PhD, MBA – VP Global Regulatory
• 20+ years leadership experience in Regulatory Affairs.
• Former Vice President of Regulatory Affairs for the Tissue and Regenerative Technologies Division of Integra LifeSciences
• Led efforts for new Class 2 and 3 medical devices, as well as an Investigational New Drug
• Responsible for CE marking all classes of medical devices under the Medical Device Directive (MDD) and new Medical Device Regulation (MDR)
• Previous regulatory leadership roles at Terumo BCT (pathogen reduction and blood processing) and Medtronic (cardiac surgery)
• Formal Education: PhD in Bioinorganic Chemistry (University of Minnesota) and MBA (Carnegie Mellon University)
FDA Emergency Use Authorization (EUA) for COVID-19

In April 2020, CytoSorbents received FDA EUA authorization for CytoSorb launching commercialization in the U.S.

- No commercial organization existed in the U.S. at the time necessitating CytoSorbents to develop a commercialization plan and team to introduce CytoSorb into the market
- Responded initially to broad interest from U.S. centers that expressed interest in CytoSorb, with clinical and technical training of many centers
- Developed sales and marketing infrastructure, including collateral marketing material
- Established CTC Registry
- Moved to proactively identify, contract, and establish 5 Distributor Network over a 3-month period, with coverage of >70% of states in the U.S.
- Presented at and attended numerous U.S. medical conferences sponsoring webinars on CytoSorb (e.g. ELSO, ICC, AmSECT, and Sanibel Perfusionist Symposium)
- Focused on KOL and reference account development
Removal of Ticagrelor – A “Breakthrough” U.S. Opportunity

Addressing an unmet medical need to minimize bleeding risk in patients undergoing cardiopulmonary bypass surgery

- Total addressable U.S. market estimated at $250M, growing to potentially $500MM as ticagrelor (Brilinta®) goes off patent and takes market share as only reversible anti-platelet agent due to CytoSorb
- Possible add-on applications include removal of Factor Xa (Xarelto®) direct oral anticoagulants (DOACS) potentially increasing the total addressable market to $1B+

<table>
<thead>
<tr>
<th>TICAGRELOR</th>
<th>Cardiac surgery (Today)</th>
<th>$250M</th>
</tr>
</thead>
<tbody>
<tr>
<td>TICAGRELOR + DOAC</td>
<td>Cardiac surgery (Future)</td>
<td>$500M</td>
</tr>
<tr>
<td>Ticagrelor + DOACS</td>
<td>Cardiac surgery</td>
<td>+$1 Billion</td>
</tr>
</tbody>
</table>
Planning for U.S. Commercialization of Ticagrelor Removal

Commercialization Overview

• Key hire – James Komsa – Vice President U.S. Sales and Marketing
• Direct sales vs direct sales/distributor blended model go-to-market launch
• Identification of key cardiac sites to identify high volume surgical sites using ticagrelor
• Target key medical meetings to begin early discussion of application within FDA guidelines
• Implement strategy for follow on applications – DOACS
• Develop reimbursement strategy
  ✓ Leverage CMS 4 year reimbursement for breakthrough medical devices (CMS-3372-F)
  ✓ Leverage FDA Payor Communication Task Force “Early Payor Feedback Program” to gain early feedback on payor expectations for clinical data
• Build team in gated steps ahead of potential U.S. approval and launch
• Establish health economics strategy
# Products and Product Pipeline

Internal and government supported development programs

<table>
<thead>
<tr>
<th>Marketed Products</th>
<th>Under Development Products</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sepsis, Critical Care, High Risk Surgery</strong></td>
<td><strong>HemoDefend RBC</strong> Purification of pRBCs</td>
</tr>
<tr>
<td><strong>ECOS-300CY®</strong> Ex Vivo Organ Perfusion For Transplant</td>
<td><strong>HemoDefend BGA</strong> Universal Plasma</td>
</tr>
<tr>
<td><strong>VETRESQ®</strong> Critical Illnesses in Animals</td>
<td><strong>CytoSorb-XL</strong> Successor to CytoSorb</td>
</tr>
<tr>
<td></td>
<td><strong>K+ontrol</strong> Severe Hyperkalemia</td>
</tr>
<tr>
<td></td>
<td><strong>ContrastSorb</strong> CT Imaging and Interventional Radiology</td>
</tr>
<tr>
<td></td>
<td><strong>DrugSorb</strong> Drug Overdose</td>
</tr>
</tbody>
</table>

Marketed

Under Development
Driving Operational Excellence

CytoSorb Device Output

- Ramped production to 7-day, 4-shift operation over a ~3 month period to address COVID surge demand
- Aggressive cost reductions (>35%) have led to significant improvements in gross margins, ~62% in 2015 to ~82% Q4 2020
World Class Partnerships to Advance Growth

Chris Cramer, MBA, MS
Vice President – Business Development
CTSO is Partnered with World Class Companies

- Global co-marketing

- Distribution in Columbia, Ecuador, Czech Republic, Finland, France, Mexico, South Korea

- Global co-marketing

- Distribution in France and Nordic countries

- Distribution in U.S. under COVID-19 EUA

- Distribution in India and Sri Lanka
Our Newest Partner:  B | BRAUN

Privately held and based in Melsungen, Germany, B. Braun is one of the world's leading healthcare companies.

With global operations in 64 countries and over 64,000 employees, B. Braun generated sales of €7.5 billion in 2019.

B. Braun Avitum manufactures and distributes products for patients with kidney disease including continuous renal replacement therapy, dialyzers, and chronic and acute hemodialysis systems like the OMNI and OMNIset.

In February 2021, CytoSorbents and B. Braun executed a global co-marketing agreement.

Goal is to leverage the world-class commercial organizations of B. Braun and CytoSorbents to:

- Increase the visibility and awareness of CytoSorb and OMNI
- Promote access to care for physicians using CytoSorb and OMNI
- Generate new sales leads for CytoSorb and OMNI
## CTSO Maintains an Active BD Pipeline

### Acute Care
- Fresenius Medical Care
- B. Braun
- Baxter
- Nipro
- Nikkiso

### Cardiac Surgery
- Terumo
- Medtronic
- ABIOMED
- MAQUET GETINGE GROUP
- LivaNova

### Pharma Companies
- Biocon
- Merck
- AstraZeneca
- Johnson & Johnson
- Roche

### Organ Transplant
- Haemotronics
- TransMedics
- XVIVO Perfusion

### HemoDefend
- CSL Behring
- Grifols
- FRESENIUS KABI
- Takeda

---

44
Building a Best-in-Class Investor Relations Program

Phillip Chan, MD, PhD
Chief Executive Officer
CytoSorbents Stock Performance

CTSO (Daily) 8.11
MA(50) 8.69
MA(200) 8.77
Volume 121,499

2020 Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2021 Feb Mar Apr May
Systematic Progress on IR Strategy

• Continued operational outperformance in our core business

• Leveraged PR and opportunities in COVID-19 and conducted more than 200 investor meetings via virtual non-deal roadshows and investor conferences to increase awareness of CytoSorbents and its current and future potential

• Increased institutional ownership to 40%, progressing towards a target of 60-65%

• Increased sell-side analyst coverage with new coverage by Leerink and Jefferies

• Eliminated financing risk through our ATM and $57.5M secondary offering in July 2020 and subsequent retirement of $15M long-term debt facility with Bridge Bank, with current cash balance of $68.5M (3/31/21)

• Drove visibility on planned U.S. approval with pending launch of STAR-T (Safe and Timely Antithrombotic Removal of Ticagrelor) pivotal trial in the U.S.

• Brought IR role in-house to drive focused outreach to institutional investors and improved investor communications
Seven Analysts Currently Covering CTSO

COWEN

SVB

Leerink

Jefferies

B R I L E Y

HCW

HCWAINWRIGHT&CO

DAWSONJAMES

MAXIM

Joshua Jennings, MD

Danielle Antalffy

Anthony Petrone, CFA

Andrew D’Silva

Sean Lee, CFA

Jason Kolbert, MBA

Jason McCarthy, PhD
Introducing Terri Anne Powers

Terri Anne Powers, MBA, IRC
Vice President – Investor Relations and Corporate Communications

• 15 years of experience in the healthcare industry as a seasoned investor relations professional and sell-side analyst

• Most recently VP Investor Relations for Diplomat Pharmacy, the largest publicly-traded independent provider of U.S. specialty pharmacy services prior to acquisition by UnitedHealth Group’s OptumRx

• Former Director of North American IR for Paris, France-based Veolia Environnement, a large cap publicly-traded global water, waste and energy leader

• Seven years as a former associate analyst at Robert W. Baird and Prudential Securities

• MBA in finance and strategic management from the University of Chicago Booth School of Business and BS in chemistry from Alma College
Focused IR Strategy Going Forward

• Communicate our story and progress, particularly on our dual path to U.S. regulatory approval, to both investors and the broader stakeholder community

• Proactive, focused, systematic, and sustained outreach to current and prospective longer-term focused institutional investors, both domestic and international

• Manage relationships with covering analysts and support efforts to add analyst coverage and increase visibility

• More streamlined communications, including revised investor materials and sharpening of messaging

• Increased visibility in the investor community via media, conferences, webinars, analyst days, and other channels

• Targeted steady news flow and integrated approach with public relations firm RubensteinPR to drive greater visibility among investors and other stakeholders
CytoSorbents is Well-Positioned for Growth

- Strong, experienced management team with continued addition of key talent to support growth initiatives
- Well-capitalized to support planned investments in manufacturing capacity, clinical programs and commercialization efforts for the coming years
- Continued growth expected in ex-US markets driven by additional partnerships, geographic expansion and label additions
- Targeted dual-path to U.S. FDA approval, with several clinical milestones expected in 2021
- Continued development of other product lines (HemoDefendRBC, VetResQ, CytoSorb-XL, etc.)
- Operational excellence to support improved efficiency and planned U.S. commercialization of CytoSorb®
Working to Save Lives – One Patient at a Time

We invite you to view the video premiere of “A CytoSorb Patient Story” from a physician who became critically ill with COVID-19 and was saved with the help of CytoSorb at www.cytosorbents.com
Q&A Session

CytoSorbents Corporation

NASDAQ: CTSO

Vice President of Investor Relations and Corporate Communications

Terri Anne Powers
tpowers@cytosorbents.com
732-482-9984

Working to Save Lives